FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
OTEZLA reduced the number and pain of oral ulcers in the 12-week placebo-controlled Phase 3 RELIEF™ study With this third…
Pharmaceuticals, Biotechnology and Life Sciences
OTEZLA reduced the number and pain of oral ulcers in the 12-week placebo-controlled Phase 3 RELIEF™ study With this third…
LONDON–(BUSINESS WIRE)–#Biotechnology–The global vitamin D testing market is expected to post a CAGR of close to 5% during the period…
DUBLIN–(BUSINESS WIRE)–The “Phenylketonuria Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025” report has been added…
LONDON–(BUSINESS WIRE)–#LifeSciences–High incidence of chronic diseases globally and the need for personalized medicine, has encouraged several technological advancements in the…
LONDON–(BUSINESS WIRE)–#Biotechnology–Several government bodies across the world are enforcing stringent regulations to tackle the adverse environmental effects of mercury emission.…
LONDON–(BUSINESS WIRE)–#Research–Predictive biomarkers can reduce unnecessary treatment and adverse effects unlike chemotherapy and targeted therapies which may cause toxic effects.…
The Essential Medicines List focuses on cancer and other global health challenges, with an emphasis on recommending effective solutions, smart…
Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune.
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million…
Data supporting the application demonstrated that the investigational subcutaneous formulation improved quality of life, reduced administration time, lowered rates of…